# A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

> **NCT03684811** · PHASE1,PHASE2 · COMPLETED · sponsor: **Forma Therapeutics, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
- Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
- Cohort 3a and 3b: Chondrosarcoma
- Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

## Interventions

- **DRUG:** FT-2102
- **DRUG:** Azacitidine
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Gemcitabine and Cisplatin

## Key facts

- **NCT ID:** NCT03684811
- **Lead sponsor:** Forma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2021-05-24
- **Final completion:** 2022-06-13
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684811, "A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03684811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*